Login to Your Account

Other News To Note

Tuesday, May 1, 2012

• Altor BioScience Corp., of Miramar, Fla., and the Melanoma Research Alliance (MRA) will jointly sponsor a University of Washington study of Altor's IL-15 superagonist, ALT-803, against metastatic melanoma. MRA selected the project under its Academic-Industry Partnership grant program.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription